CYP19A1 and breast cancer: Under these conditions, 27HC can still promote ER+ BC progression even under the pressure of endocrine therapies like aromatase inhibitor treatments since it can freely access the unaffected estrogen receptor driving the transcription of tumor growth-promoting genes.